vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SITIME Corp (SITM). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $113.3M, roughly 1.5× SITIME Corp). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 66.3%). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
ESPR vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $113.3M |
| Net Profit | — | $9.2M |
| Gross Margin | — | 56.4% |
| Operating Margin | 50.6% | 1.6% |
| Net Margin | — | 8.1% |
| Revenue YoY | 143.7% | 66.3% |
| Net Profit YoY | — | 148.7% |
| EPS (diluted) | $0.32 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $113.3M | ||
| Q3 25 | $87.3M | $83.6M | ||
| Q2 25 | $82.4M | $69.5M | ||
| Q1 25 | $65.0M | $60.3M | ||
| Q4 24 | $69.1M | $68.1M | ||
| Q3 24 | $51.6M | $57.7M | ||
| Q2 24 | $73.8M | $43.9M | ||
| Q1 24 | $137.7M | $33.0M |
| Q4 25 | — | $9.2M | ||
| Q3 25 | $-31.3M | $-8.0M | ||
| Q2 25 | $-12.7M | $-20.2M | ||
| Q1 25 | $-40.5M | $-23.9M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $-29.5M | $-19.3M | ||
| Q2 24 | $-61.9M | $-26.8M | ||
| Q1 24 | $61.0M | $-28.7M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 51.9% | ||
| Q1 25 | — | 50.3% | ||
| Q4 24 | — | 52.6% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 49.1% | ||
| Q1 24 | — | 53.5% |
| Q4 25 | 50.6% | 1.6% | ||
| Q3 25 | -11.4% | -19.2% | ||
| Q2 25 | 8.6% | -35.4% | ||
| Q1 25 | -34.0% | -46.6% | ||
| Q4 24 | -6.4% | -33.8% | ||
| Q3 24 | -31.0% | -43.1% | ||
| Q2 24 | 3.5% | -73.7% | ||
| Q1 24 | 52.5% | -106.1% |
| Q4 25 | — | 8.1% | ||
| Q3 25 | -35.9% | -9.6% | ||
| Q2 25 | -15.4% | -29.0% | ||
| Q1 25 | -62.2% | -39.6% | ||
| Q4 24 | — | -27.6% | ||
| Q3 24 | -57.2% | -33.5% | ||
| Q2 24 | -83.9% | -61.0% | ||
| Q1 24 | 44.3% | -86.9% |
| Q4 25 | $0.32 | $0.44 | ||
| Q3 25 | $-0.16 | $-0.31 | ||
| Q2 25 | $-0.06 | $-0.84 | ||
| Q1 25 | $-0.21 | $-1.01 | ||
| Q4 24 | $-0.14 | $-0.80 | ||
| Q3 24 | $-0.15 | $-0.83 | ||
| Q2 24 | $-0.33 | $-1.16 | ||
| Q1 24 | $0.34 | $-1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.2B |
| Total Assets | $465.9M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.1B | ||
| Q2 25 | $-433.5M | $1.1B | ||
| Q1 25 | $-426.2M | $692.5M | ||
| Q4 24 | $-388.7M | $699.7M | ||
| Q3 24 | $-370.2M | $696.2M | ||
| Q2 24 | $-344.2M | $692.5M | ||
| Q1 24 | $-294.3M | $696.2M |
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.3B | ||
| Q2 25 | $347.1M | $1.3B | ||
| Q1 25 | $324.0M | $872.1M | ||
| Q4 24 | $343.8M | $885.0M | ||
| Q3 24 | $314.1M | $877.9M | ||
| Q2 24 | $352.3M | $878.6M | ||
| Q1 24 | $373.1M | $942.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $25.4M |
| Free Cash FlowOCF − Capex | — | $13.0M |
| FCF MarginFCF / Revenue | — | 11.5% |
| Capex IntensityCapex / Revenue | 0.0% | 10.9% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | — | $35.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $25.4M | ||
| Q3 25 | $-4.3M | $31.4M | ||
| Q2 25 | $-31.4M | $15.3M | ||
| Q1 25 | $-22.6M | $15.0M | ||
| Q4 24 | $-35.0M | $13.5M | ||
| Q3 24 | $-35.3M | $8.2M | ||
| Q2 24 | $-7.2M | $-181.0K | ||
| Q1 24 | $53.8M | $1.7M |
| Q4 25 | — | $13.0M | ||
| Q3 25 | — | $26.3M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $-2.4M | ||
| Q3 24 | $-35.5M | $-6.7M | ||
| Q2 24 | $-7.3M | $-2.7M | ||
| Q1 24 | $53.8M | $-1.2M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 31.5% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -2.1% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | -68.7% | -11.6% | ||
| Q2 24 | -9.9% | -6.3% | ||
| Q1 24 | 39.0% | -3.6% |
| Q4 25 | 0.0% | 10.9% | ||
| Q3 25 | 0.0% | 6.1% | ||
| Q2 25 | 0.0% | 26.2% | ||
| Q1 25 | 0.0% | 27.0% | ||
| Q4 24 | 0.0% | 23.3% | ||
| Q3 24 | 0.3% | 25.7% | ||
| Q2 24 | 0.1% | 5.8% | ||
| Q1 24 | 0.1% | 8.8% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SITM
Segment breakdown not available.
